Patients with ASPSCR1-TFE3 fusion achieve better response to ICI based combination therapy among TFE3-rearranged renal cell carcinoma
在TFE3重排的肾细胞癌中,ASPSCR1-TFE3融合基因阳性患者对基于免疫检查点抑制剂的联合治疗反应更佳。
期刊:Molecular Cancer
影响因子:33.9
doi:10.1186/s12943-024-02044-5
Zhao, Junjie; Tang, Yanfeng; Hu, Xu; Yin, Xiaoxue; Chen, Yuntian; Chen, Junru; Liu, Haoyang; Liu, Haolin; Liang, Jiayu; Zhang, Xingming; Zhao, Jinge; Zhu, Sha; Ni, Yuchao; Wang, Zhipeng; Dai, Jindong; Wang, Zilin; Zhang, Yaowen; Yao, Jin; Chen, Ni; Shen, Pengfei; Liu, Zhenhua H; Zeng, Hao; Sun, Guangxi X
CR1
肿瘤
肿瘤免疫
肾癌
TFE3
细胞生物学
免疫/内分泌